White Pine Investment CO Arcus Biosciences, Inc. Transaction History

White Pine Investment CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 28, 2022	SELL	$31.38 - $48.47 $594,305 - $917,973	-18,939 Closed	0 $0
Q1 2021 May 03, 2021	BUY	$26.16 - $41.39 $495,444 - $783,885	18,939 New	18,939 $532,000
Q4 2020 Jan 22, 2021	SELL	$17.0 - $32.36 $321,963 - $612,866	-18,939 Closed	0 $0
Q3 2020 Nov 02, 2020	BUY	$17.14 - $25.47 $324,614 - $482,376	18,939 New	18,939 $325,000
Q2 2020 Aug 13, 2020	SELL	$13.97 - $36.56 $264,577 - $692,409	-18,939 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$7.29 - $13.38 $138,065 - $253,403	18,939 New	18,939 $151,000
Q1 2019 Apr 23, 2019	SELL	$8.95 - $12.49 $169,504 - $236,548	-18,939 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$9.74 - $14.5 $184,465 - $274,615	18,939 New	18,939 $204,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of White Pine Investment CO, based on Form 13F filings with the SEC.

Stay updated on White Pine Investment CO with notifications on news.